mAbxience received the Innovation award in the Innovative Product category for its drug, Novex®, the first biosimilar monoclonal antibody developed in Latin America. Every year, the most noteworthy scientific discoveries developed in Argentina are given recognition by the Argentinian Ministry of Science, Technology and Productive Innovation (MINCYT).
The Director of Innovation and Technological Development in Grupo Insud, Graciela Ciccia, picked up the award at a ceremony held on 17 October. She did so on behalf of the Consortium for Research, Development and Innovation (R&D&I)
Novex®, a drug used in the treatment of Non-Hodgkin’s lymphoma, chronic lymphatic leukaemia and rheumatoid arthritis, was brought to the Argentinian market just one year ago.
This biosimilar is produced in the mAbxience pharmADN plant and is carried out under the public-private consortium composed of Chemo Romikin, Elea, pharmADN, the Universidad Nacional de Quilmes, the Instituto de Oncología Ángel Roffo (UBA), and the Instituto Nacional de Tecnología Industrial (INTI).
The INNOVAR awards, presented by the MINCYT, recognise technological scientific discoveries, innovations and accomplishments in Argentina, through various categories, including the Applied Research category and the University Innovation category.